 SAN DIEGO, Nov. 11, 2020 GLOBE NEWSWIRE -- Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from its ongoing Phase 1 clinical trial evaluating TK216, an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific ETS family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma. The data update will be delivered in an oral presentation at the Connective Tissue Oncology Society CTOS 2020 Virtual Annual Meeting, and a copy of the presentation will be available online at starting on November 11, 2020. 